Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Key Points: A high frequency of RAS/RAF mutations and recurrent mutations in PDGFRA and JAK3 were found in relapsed multiple myeloma patients. Patients with NRAS, but not KRAS, mutation exhibited significantly reduced sensitivity to bortezomib but not high-dose dexamethasone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 1×
“In solid tumors, including colorectal,(9) lung,(8) and pancreatic cancer,(8) KRAS is mutated much more frequently than NRAS; the reverse is true in some hematologic cancers such as acute lymphoblastic and chronic myelomonocytic leukemias, and Hodgkin lymphoma.(8,10) Myeloma does not exhibit such predominance; instead,…”
BackgroundThe genetic architecture of multiple myeloma
Morgan, G. J., Walker, B. A., & Davies, F. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3257 · Cited by 913
Haigis, K. M., Kendall, K. R., Wang, Y., Cheung, A., Haigis, M. C., Glickman, J. N., Niwa-Kawakita, M., Sweet-Cordero, A., Sebolt-Leopold, J., Shannon, K. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.115 · Cited by 610
Liu, P., Leong, T., Quam, L., Billadeau, D., Kay, N., Greipp, P., Kyle, R., Oken, M., & Van Ness, B. (1996) · Blood · doi:10.1182/blood.v88.7.2699.bloodjournal8872699 · Cited by 215 · cited 2×
“Myeloma does not exhibit such predominance; instead, there appears to be high and approximately equal rates (;20%) of KRAS and NRAS mutation.(11,12)”
BackgroundResult
Cited by
Walker, B. A., Boyle, E. M., Wardell, C. P., Murison, A., Begum, D. B., Dahir, N. M., Proszek, P. Z., Johnson, D. C., Kaiser, M. F., Melchor, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.1503 · Cited by 567
PDGF receptor signaling networks in normal and cancer cells
Demoulin, J.-B., & Essaghir, A. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.03.003 · Cited by 238
Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options
van Andel, H., Kocemba, K. A., Spaargaren, M., & Pals, S. T. (2019) · Leukemia · doi:10.1038/s41375-019-0404-1 · Cited by 188
Xu, J., Pfarr, N., Endris, V, Mai, E. K., Md Hanafiah, N. H., Lehners, N., Penzel, R., Weichert, W., Ho, A. D., Schirmacher, P., et al. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.36 · Cited by 89
Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
Adamia, S., Bhatt, S., Wen, K., Chyra, Z., Fell, G. G., Tai, Y.-T., Pioso, M. S., Abiatari, I., Letai, A., Dorfman, D. M., et al. (2022) · Leukemia · doi:10.1038/s41375-021-01475-z · Cited by 24
Self-citation
Metadata
- Authors
- Mulligan, G., Lichter, D. I., Di Bacco, A., Blakemore, S. J., Berger, A., Koenig, E., Bernard, H., Trepicchio, W., Li, B., Neuwirth, R., Chattopadhyay, N., Bolen, J. B., Dorner, A. J., van de Velde, H., Ricci, D., Jagannath, S., Berenson, J. R., Richardson, P. G., Stadtmauer, E. A., Orlowski, R. Z., Lonial, S., Anderson, K. C., Sonneveld, P., San Miguel, J. F., Esseltine, D.-L., & Schu, M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-01-30
- Volume
- 123
- Issue
- 5
- Pages
- 632-639
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2035478227
- Cited by
- 118
- References
- 5
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. https://app.cochat.ai/papers/10.1182/blood-2013-05-504340
- The paper
- Mulligan, G., Lichter, D. I., Di Bacco, A., Blakemore, S. J., Berger, A., Koenig, E., Bernard, H., Trepicchio, W., Li, B., Neuwirth, R., Chattopadhyay, N., Bolen, J. B., Dorner, A. J., van de Velde, H., Ricci, D., Jagannath, S., Berenson, J. R., Richardson, P. G., Stadtmauer, E. A., . . . Schu, M. (2014). Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood. https://doi.org/10.1182/blood-2013-05-504340
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.